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Metastasis is an extremely complex process that accounts for most cancer-related deaths. Malignant primary tumors can be
removed surgically, but the cells that migrate, invade, and proliferate at distant organs are often the cells that prove most diﬃcult
to target therapeutically. There is growing evidence that host factors outside of the primary tumors are of major importance in
the development of metastasis. Recently, we have shown that the bromodomain-containing protein 4 or bromodomain 4 (Brd4)
functions as an inherited susceptibility gene for breast cancer progression and metastasis. In this paper, we will discuss that host
genetic background on which a tumor arises can signiﬁcantly alter the biology of the subsequent metastatic disease, and we will
focus on the role of Brd4 in regulating metastasis susceptibility.
1.Introduction
Breast cancer is the most common cancer diagnosed in
women worldwide. In the United States the estimates for
2010 were 209,060 new cases of invasive breast cancer
and 40,230 deaths [1]. The main cause of breast cancer-
relateddeathsismetastaticdisease.Theoverall5-yearrelative
survival of patients with metastatic breast cancer is 23%,
while the relative survival of breast cancer patients with
nonmetastatic tumors is 98% [2]. Patients who have no
evidence of tumor dissemination at the time of diagnosis are
still at risk of metastatic disease. Approximately one-third of
women who are sentinel lymph node negative at the time of
surgicalresectionofthebreastprimarytumorwilleventually
develop clinically detectable secondary tumors [3]. There-
fore, understanding the mechanisms governing tumor dis-
semination anddeveloping newstrategies tocontroloreﬀec-
tivelytreatpatientswithoratriskofmetastaticdiseasewould
signiﬁcantly improve the overall outcome of the disease.
Metastasis is a multistep complex process that involves
the detachment of tumor cells from the primary tumor,
migration and invasion through the surrounding tissues
and basement membranes, intravasation and survival in the
small blood vessels or lymphatic channels, and colonization
in a distant target organ. These steps are usually followed
by extravasation into the surrounding tissue, survival in the
foreign microenvironment, proliferation, and induction of
angiogenesis (Figure 1). It has become apparent that the vast
majority of tumor cells within the primary tumor and also
the disseminated tumor cells will not form distant metas-
tases, either because they die or remain dormant [4]. The
dormancyphenomenonprobablyexplainswhatisseeninthe
clinic in which some cancer patients remain free of clinical
evidence of metastatic disease for years or even decades after
primary tumor resection, and after this prolonged period
of time these patients show signs of tumor relapse. The
development of the primary tumor microenvironment is
also an important determinant of tumor dissemination;
this tumor microenvironment may inﬂuence the release of
cancer cells into the blood and the lymphatic systems and
subsequently promote continued survival and proliferation
at the secondary site. It has been well known that the
interactionbetweentumorcellsandtheirmicroenvironment
is important for establishing metastatic colonies and for2 International Journal of Breast Cancer
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Figure 1 :T h es t e p so ft h em e t a s t a t i cc a s c a d e .
deﬁning the balance between dormancy and malignant
growth [5, 6]. Furthermore, the microenvironment of meta-
static tumor cells has recently been thought to play a major
role in tumor progression. Although tumor cells may be
continually released from the primary site, relatively few of
them are able to eﬃciently form macrometastasis. What are
the factors controlling this important step?
In this paper we will discuss a more global view of
host-tumor interactions in which the metastatic potential of
tumors is an inherent component of cells forming the pri-
mary tumor mass at an early time in tumor progression. We
will also discuss the association of two genes, Brd4 and Sipa1
(signal-induced proliferation-associated 1), with mammary
tumor progression in both the mouse and the human. Here,
we will focus on the role that the metastasis susceptibility
gene Brd4 plays in the regulation of extracellular matrix
(ECM)geneexpressionandsubsequentlymetastaticprogres-
sion.
2.GeneticBackground Plays an Important Role
inMetastasis
Studies from our laboratory have demonstrated that the
inherited polymorphism, or the genetic background on
which a tumor arises, plays an important role in determining
the probability that the given tumor will progress to me-
tastatic disease. These ﬁndings are based on a series of
genetic mapping studies using the highly metastatic polyoma
middle-T (PyMT) transgenic mammary mouse model. This
mouse expresses the mouse polyoma virus middle-T antigen
in the mammary epithelium of FVB/N inbred mice [7]
from an early age [8], which results in the development
of highly aggressive mammary tumors that metastasize to
the lung with high frequency [7]. Speciﬁcally, when the
male PyMT transgenic mouse was bred to diﬀerent inbred
strains,theF1progenyshowedsigniﬁcantvariationintumor
characteristics, such as tumor latency, growth kinetics, and
metastatic capacity [9]. It is important to point out that
these tumors were all induced by the same oncogenic event,
the activation of the PyMT transgene. Subsequent analysis
identiﬁed several interacting quantitative trait loci (QTL),
some of which were found to map to homologous regions
associated with loss of heterozygosity in human breast
cancer [8, 10, 11]. Together, these ﬁndings suggest that
inherited germline polymorphisms may contribute to the
age of onset in human breast cancer and also the ability
of tumor cells to metastasize. Further investigation of these
earlier observations identiﬁed the ﬁrst known polymorphic
metastasis susceptibility gene, the Rap-GTPase activating
protein (GAP) SIPA1 [12]. Experimental manipulation of
cellular Sipa1 mRNA levels in a highly metastatic mouse
mammary tumor cell line showed that subtle diﬀerences in
Sipa1 levels signiﬁcantly aﬀected the ability of the cells to
colonize to the lungs, while not impacting primary tumor
kinetics [12]. Studies of human breast cancer have suggested
that SIPA1 germline polymorphisms are associated with
aggressive disease behavior and with indicators of poor
prognosis [13, 14], suggesting that Sipa1 m a yp l a ya n
important role in establishing metastatic susceptibility in
humans as well as in mice.
3. Inherited Polymorphisms and ECM Gene
Expression Proﬁle
We have shown so far that hereditary polymorphisms
modulate metastatic potential. To further study whether
genetic polymorphisms could be an important factor in
the induction of prognostic signature proﬁles, previously
published metastasis-predictive gene expression signatures
were examined both in the mouse and in humans. ECM
genes were found to be common components of the
metastasis-predictive gene signature in both human breast
tumors [15–17] and in PyMT-induced mouse mammary
tumors[18,19],suggestinganimportantassociationofthese
genes with breast cancer progression. Brieﬂy, the ECM
components constitute a structure that is not only essential
for the maintenance of tissue integrity but is also important
for regulating cell migration. Historically, tumor interaction
with the basement membrane was deﬁned as the critical
event in tumor invasion that signals the initiation of the
metastatic cascade. Many steps in metastasis formation
require speciﬁc interactions with the ECM [20]. The nature
and degree of this interaction will change from step to step
during the metastatic process. However, the type of speciﬁc
interactions between tumor cells and the ECM might be
inﬂuenced by the type of tumor cells and the type of matrix
in which they reside. For example, tumor cells may respond
diﬀerently to various extracellular matrices and stromal cells
that are encountered during metastasis formation, and this
might result in the emphasis of some steps over others at
particularpointsinthemetastaticcascade(reviewedin[21]).
A study by Bergamaschi and colleagues has portrayed
thetumor-stromacomposition ofinvasivebreastcarcinomas
by characterizing the ECM components [22]. Diﬀerential
expression of ECM-related genes identiﬁed four distinct
groups. The ECM classiﬁcation was recapitulated in a set
of early-stage primary breast carcinomas [22, 23]. Survival
analysis on the early-stage breast carcinoma dataset showed
signiﬁcant diﬀerences in clinical outcome among the various
ECM subclasses [22]. Several studies that explored gene
expression diﬀerences of primary breast and metastatic
lymph node tumors have shown that genes involved inInternational Journal of Breast Cancer 3
changes in extracellular matrix stability are critical for the
early stages of the metastatic process [24–27]. Furthermore,
ECM gene dysregulation has been shown to be a very
prominent feature of metastatic progression and may well
explain why highly metastatic mouse mammary tumor cell
lines are typically more adhesive, invasive, and migratory
than the less metastatic lines [28]. To determine whether the
ECM dysregulation is under germline control, the AKXD
recombinant inbred mice (RI) [29]w e r eu s e dt od e ﬁ n e
ECM expression quantitative trait loci (eQTL). An eQTL is
a genetically deﬁned genomic locus associated with variation
of gene expression, in this case ECM gene expression [30].
We chose the AKXD RI mice because they are considered
a useful tool for the study of germline-encoded metastatic
propensity since they are derived from a highly metastatic
strain,AKR/J,andaweaklymetastaticstrain,DBA/2J[9].We
found that the most signiﬁcant eQTL in these mice is located
on proximal mouse chromosome 17. This eQTL colocalizes
to the peak region of linkage of a metastasis susceptibility
QTL [31]. Both of these eQTL and metastasis loci colocalize
and reside in a genomic region that contains the gene Brd4,
suggesting that Brd4 modulates ECM gene expression.
4.Brd4 Is a PotentialMetastasis
SusceptibilityGene
BRD4 is the mammalian member of the BET (bromodomain
and extra-terminal) family [32, 33], whose members carry
two tandem bromodomains [34, 35]. BRD4 has been shown
to regulate cell growth by acting at diﬀerent stages of the
cell cycle and also to interact with acetylated chromatin
through its two bromodomains [32, 33]. Given the apparent
modulation of ECM gene expression, we further investigated
the possibility that Brd4 might be a metastasis susceptibility
gene. Indeed, we found that ectopic expression of Brd4 in a
highly metastatic mouse mammary tumor cell line reduces
both primary tumor growth and metastatic capacity in our
mousemodel[36].In vitro analysesshowedthatBrd4ectopic
expression reduces both cell invasion and cell migration and
also reduces cellular growth in three-dimensional cultures
[36]. These data are consistent with our previous ﬁndings
that Brd4 modulates ECM gene expression. Microarray gene
expression analysis of the cell lines ectopically expressing
Brd4, further conﬁrmed that Brd4 is a regulator of at least
some of the ECM gene family members [36]. Some of the
ECM genes that were altered by ectopic expression of Brd4
are the collagen genes Col1a1, Col5a3, Col6a2, the ﬁbrillin
gene Fbn1 and Serping1, indicating that Brd4 is a causative
factor in the transcriptional regulation of these genes [36].
4.1. Brd4 and Sipa1 Interaction and Metastatic Progression.
BRD4 has been previously found to interact in vitro and in
vivo with the metastasis modiﬁer SIPA1 [37]. This interac-
tion modulates the enzymatic activity of SIPA1 by increasing
its RAP-GAP activity. The N-terminus bromodomain II
of BRD4 was shown to be the domain where BRD4 and
SIPA1 interact [37]. Deletion of bromodomain II resulted
in further suppression of primary tumor growth and lung
metastasismediatedbyBrd4andalsoinducedaconversionto
a more epithelial state [38]. These results are consistent with
our previous ﬁndings that SIPA1 is associated with greater
malignancy [12]. It is important to mention here that BRD4
and SIPA1 were shown to regulate each other’s subcellular
localization, with BRD4 being redirected from the nucleus
to the cytoplasm [37]. It is possible that the interaction
between these two proteins contributes to tumor progres-
sion, and also the activity of Brd4 might be modulated by
compartmentalization; however, the mechanism by which
this occurs has yet to be explored. One possibility could
be that there is a balance between BRD4 and SIPA1 within
the cell. Under normal conditions BRD4 and SIPA1 interact
in the nucleus while the cytoplasmic SIPA1 does not take
part in this interaction. Upon Brd4 overexpression, SIPA1
accumulates in the perinuclear region and in some cases in
thenucleusnearthenuclearmembrane[37].However,when
Sipa1 is overexpressed, a large fraction of BRD4 gets moved
to the cytoplasm leading to a more malignant phenotype.
Our results suggest that the loss of the ability of SIPA1
to relocalize or sequester the bromodomain II mutant to
the cytoplasm would increase the nuclear concentration of
BRD4, leading to a more diﬀerentiated state and a less
malignant phenotype. At this point it is not known whether
the BRD4-SIPA1 interaction inﬂuences the small GTPase
RAP1 levels within the tumor cell. RAP1 activity has been
shown to play an important role in tumor formation and
progression to malignancy [39, 40]. Further investigations
of the BRD4-SIPA1 relationship and the inﬂuence that it
could have on RAP1 levels might reveal a novel mechanism
associated with malignant progression.
4.2. Brd4 and Regulation of Epithelial-to-Mesenchymal Tran-
sition (EMT). BRD4 is known to be a transcriptional regula-
tor.AsmentionedearlierBRD4containstwobromodomains
that bind acetylated histones [32] .Ar e c e n tr e p o r th a s
shown that the extraterminal (ET) domain of BRD4 is an
important transcriptional regulatory domain [41]. The C-
terminaldomaincontainsasingledeﬁneddomainthatbinds
thetranscriptionalelongationfactorP-TEFb[42].BRD4also
contains regions of high serine, proline, and glutamine con-
tent of unknown function. Indeed, microarray gene expres-
sion analysis of the cell lines that ectopically express Brd4
has revealed that Brd4 modulates the expression of genes
involved in processes such as cellular proliferation, cell
cycle progression, and chromatin remodeling [36]. Other
processes that are critical for metastasis, such as cytoskeletal
remodeling, cell adhesion, and as mentioned earlier ECM
expression regulation, were also regulated by Brd4 [36].
Furthermore, microarray gene expression analysis of cell
lines that express a C-terminal deletion of Brd4 show
modulation of other classes of genes involved in EMT and
stem cell conversion processes [38].
EMT is a multigstep process in which the cells acquire
molecular changes that lead to a loss of cell-cell junctions,
dysfunctional cell-cell adhesion, and rearrangement of the
cytoskeleton, leading to a loss of polarity and the acquisi-
tion of a more spindle-shape morphology [43–48]. These
alterations might eventually promote cancer cell progression
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surrounding tissues. Indeed, several studies have associated
EMT with cancer progression and metastasis [49–52]. For
example, EMT markers have been found to be present in
invasive breast cancer especially in the invasion-metastasis
cascade [47, 53]. Recently, a concept of the “migratory
cancer stem cell” has been described [54], in which a tumor
cell possesses both stemness and motility properties. It is
suggested that cancer stem cells that have undergone EMT
can disseminate, and those that retain stem-cell functionality
can form metastatic colonies [54]. More recently the EMT
processhasalsobeenlinkedtotheabilityofself-renewal[55].
Current thinking suggests that disseminated cancer cells
may need to acquire self-renewal properties similar to those
exhibited by the stem cells, in order to achieve formation of
macroscopic metastases [55] .T h er o l eo fE M Ti nt u m o r -
initiating cells has also been described in human speci-
mens. Breast cancer tumor-initiating cells and mesenchymal
claudin-low-subtype cells show an association based on gene
expression pattern [56]. Furthermore, higher expression
of mesenchymal genes was detected in breast cancer tumors
before and after treatment with letrozole, indicating that the
epithelial cancer cells have undergone EMT [56].
Ectopic expression of the C-terminal deletion mutant of
Brd4 (ΔC) in a highly metastatic cell line induced signiﬁcant
morphological and physiological changes reminiscent of
EMT-like and cancer stem cell-like properties [38]. Microar-
ray gene expression analysis of these cell lines demonstrated
that ectopic expression of the ΔC mutant modulated the
expression of some previously described EMT markers and
stem cell markers. It is important to point out here that this
mutant still contains the P-TEFb-binding domain suggesting
that EMT-like and stem cell-like changes appear to be
mediatedbythisP-TEFb-bindingregion.Themechanismon
how this might occur is currently under investigation.
4.3. Brd4 Isoforms and Metastasis Regulation. Brd4 has two
alternatively spliced variants that diﬀer in the coding region
and have a distinct 3 UTR. Both isoforms have the same N-
terminal region containing the chromatin-binding bromod-
omains and the serine-rich domain; however, the C-terminal
proline-rich and P-TEFb-binding domains are absent in the
shorter isoform. We have found that ectopic expression of
the short isoform enhances metastatic colonization [38], as
opposed to that seen by ectopic expression of the longer
isoform [36]. This would suggest that the Brd4 short isoform
might be a competitive inhibitor of the longer isoform and
that this inhibition would increase the ability of tumors
to progress to metastatic disease. This also suggests that
metastaticsusceptibilitymightbeencodedbyaratiobetween
the two isoforms. The above data also suggest that the
carboxy terminal half of the full-length isoform mediates
the ability of Brd4 to suppress progression and metastasis.
This was conﬁrmed by the ﬁnding that expression of the
C-terminal ΔCm u t a n to fBrd4 increased lung colonization
[38]. This increased malignancy is consistent with the in
vitro data that cells expressing this mutant possess EMT-
and stem cell-like properties. It is not known at this point
whether the ratio between the two Brd4 isoforms inﬂuences
the expression of Sipa1 or vice versa. It would also be highly
interesting to determine whether the BRD4 short isoform
and SIPA1 could change each other’s subcellular localization
as seen with the longer isoform. The ratio between these
three proteins and their cellular localization could be critical
for malignant progression.
It is important to mention here that, in rare midline
carcinomas, a highly malignant form of human squamous
carcinoma, the BRD4 short isoform is frequently fused to
the NUT (nuclear protein in testis) oncogene via an intronic
translocation [57–60]. The major oncogenic eﬀect of BRD4-
NUT fusion protein appears to lie in its ability to arrest the
diﬀerentiation of the so-called NUT-midline carcinoma cells
[59]. This is consistent with our ﬁndings that the shorter
Brd4 isoform promotes metastatic capacity and also that the
competitive inhibition of the longer Brd4 isoform would
increase the ability of tumors to progress to metastatic
disease [38].
4.4. Brd4 Isoforms Expression and Gene Expression Signatures.
Several studies have demonstrated that primary tumors with
a higher propensity to metastasize exhibit gene expression
patterns that predict the likelihood of metastatic potential
[15–17]. As mentioned earlier, Brd4 is responsible, at least
partially, for the presence of ECM components in the meta-
static-predictive gene signatures [36], suggesting that Brd4
itselfmightbeapredictiveofsurvival.Wehavefoundthatthe
Brd4 long isoform induces a gene expression signature that
predictsgoodoutcomeinhumanbreastcancerdatasets.This
suggests that Brd4 activation is an important determinant
in the overall likelihood of relapse and/or survival [36]. The
Brd4 gene expression signature was also able to stratify breast
cancer patients with lymph-node-negative and estrogen-
receptor-positive at presentation into high- and low-risk
patients [36]. The gene expression signature induced by the
Brd4 short isoform, however, predicted poor outcome in
these human breast cancer datasets [38], conﬁrming that
the shorter isoform might be a competitive inhibitor of
the longer isoform. Additionally, the Brd4 long- and short-
isoform gene expression signatures were compared to a 19-
gene signature that was deﬁned by correlating tumor growth
expression, histological grade, and survival [61]. We found
that the Brd4 longer isoform signature matches low-grade
G1 breast cancer tumors while the shorter isoform matches
high-grade G3 tumors [36, 38]. These observations were
completely consistent with our in vivo data. The outcome
prediction and the signature convergence might be of
potential importance in the clinic where it could improve the
stratiﬁcation of patients into diﬀerent subtypes and in turn
enable clinicians to tailor treatments for individual patients.
5.Brd4 as aTherapeutic Target
Selective inhibitors of the BET family members have been
recently developed [62–65]. A competitive binding of the
small molecule inhibitor JQ1, for example, was shown to
displace the BRD4 fusion oncoprotein from chromatin,
promoting squamous diﬀerentiation and speciﬁc anti-
proliferative eﬀects [63]. These eﬀects were seen in BRD4-
dependent cell lines and patient-derived xenograft modelsInternational Journal of Breast Cancer 5
[63]. In another study, Zuber and colleagues studied acute
myeloid leukemia (AML), which is an aggressive hematopoi-
etic malignancy that is often associated with aberrant
chromatin states [65]. Suppression of Brd4 by shRNA or
by JQ1 compound led to robust antileukemic eﬀects both
in vivo and in vitro. Brd4 inhibition also led to myeloid
diﬀerentiation and leukemia stem-cell depletion [65]. At this
point it is not known whether the small-molecule inhibition
ofBrd4would have any eﬀectonbreastcancerandmetastatic
progression. However, the recent ﬁndings establish Brd4 as a
promising target for therapeutic intervention.
6. Conclusions
It is clear that the genetic background is an important
determinant of tumor progression. The genetic background
impacts not only the primary tumor but all of the tissues,
which play a role in the establishment of the microenviron-
mentinbothprimaryandmetastatictumorcells.Thiswould
suggest that an earlier prognosis in nontumor tissues should
be possible even before cancer develops. This is only possible
if a suﬃcient fraction of metastatic risk is encoded by germ-
linepolymorphisms,ratherthanautonomoussomaticevents
within the tumor.
Our recent data suggest that the metastasis susceptibility
gene BRD4 appears to play a signiﬁcant role in establishing
transcriptional programs that predict breast cancer outcome
via a balance between the tumor- and metastasis-suppressive
long isoform and the metastasis-promoting short isoform.
Given the fact that BRD4 regulates important intermediates
and processes within the metastatic cascade suggests that
BRD4, and possibly other metastatic susceptibility genes,
may be altering the risk of developing distant metastases by
predisposing the tumors of high-risk patients to undergo
conversion to a more dediﬀerentiated or primitive state.
Finally, the Brd4 gene expression signature identiﬁed could
be applied as a useful predictive tool by identifying those
patients with low risk of relapse at presentation. This com-
bined with the traditional clinical variables such as lymph
node-negative and ER-positive patients would facilitate the
identiﬁcation and the initiation of new treatment protocols
that could be applied for individual patients.
Glossary
Invasion. A process that initiates metastasis and consists of
changes in tumor cell adherence to the extracellular matrix,
proteolysis of the extracellular matrix and the surrounding
tissues and migration through these tissues.
Intravasation. Theentryoftumorcellsintothebloodstream.
Extravasation. Theescapeoftumorcellsfromthecirculation
into the parenchyma of an organ.
Colonization. A process by which disseminated tumor cells
grow to form clinically detectable metastatic lesions.
Angiogenesis. The formation of new blood vessels that are
needed for the growth of the primary tumor and metastases.
Dormancy. A period in which the cells are in a non-dividing
state.
Polymorphism. A variation within a gene where two or more
alleles exist at a frequency of at least 1% in the general
population.
Extracellular Matrix. The matrix that is laid down by cells in
which they adhere and move.
Expression Quantitative Trait Locus (eQTL). Ag e n e t i c a l l y
deﬁned genomic locus associated with variation of expres-
sion of the genes that underlie the trait in question.
Epithelial-to-Mesenchymal Transition (EMT). Ap o t e n t i a l
mechanism in tumor progression by which some cancer cells
acquire the ability to convert from polarized epithelial cells
to mesenchymal motile cells facilitating metastasis at distant
sites.
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